Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer - 1 Sept 2022

Hwang Mary, Medley Sarah, Shakeel Faisal, Vanderwerff Brett, Zawistowski Matthew, Kidwell Kelley M, Hertz Daniel L

Abstract excerpt

PURPOSE: Cyclophosphamide is a commonly used cancer agent that is metabolically activated by polymorphic enzymes. This study aims to investigate the association between predicted activity of candidate pharmacogenes with severe toxicity during cyclophosphamide treatment. METHODS: Genome-wide genetic data was collected from an institutional genetic data repository for CYP2B6, CYP3A4, CYP2C9, CYP2C19, GSTA1, GSTP1,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aldehyde Dehydrogenase 1 Family
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2B6

Share to Genotype

Share to Neoplasms

Share to Pharmacogenetics

Share to Retinal Dehydrogenase

Source

Identifiers

PMID: 35606478
DOI: 10.1007/s00520-022-07118-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer.PMID 35606478Read ↗

Association of ALDH1A1 Polymorphism With Toxicity From Cyclophosphamide TreatmentSemantic proximity Read ↗

The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomesSemantic proximity Read ↗

Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.Semantic proximity Read ↗

Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastomaSemantic proximity Read ↗

Influence of Genetic Variation of GST, CYP, and ABC on the Safety and Efficacy of Cyclophosphamide-Based Therapy.Semantic proximity Read ↗

The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.Semantic proximity Read ↗

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.Semantic proximity Read ↗

Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.Semantic proximity Read ↗

Cyclophosphamide pharmacogenomics and their effect on its bioactivation and pharmacokineticsSemantic proximity Read ↗

Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.Semantic proximity Read ↗

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast CancerSemantic proximity Read ↗

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.